Lilly May Need To Reassess Baricitinib Market After FDA Advisory Committee
Executive Summary
During a mixed review by the US FDA's Arthritis Advisory Committee, panelists suggested that risks potentially associated with Lilly/Incyte's JAK inhibitor would be acceptable for a more limited patient population.
You may also be interested in...
Lilly/Incyte’s Olumiant Breezes Ahead of JAK Pack In Atopic Dermatitis
Lilly/Incyte’s JAK inhibitor baricitinib is the first of its class to report positive Phase III data in atopic dermatitis. But will the dosing worries of Olumiant’s rheumatoid arthritis indication spoil the party?
Pfizer's Xeljanz Pushed By New Tailwind From Approval In Ulcerative Colitis
FDA approved the JAK inhibitor as the first oral medicine for moderate to severe ulcerative colitis, providing Pfizer with fertile new commercial ground for the blockbuster drug.
A Q&A With Lilly Biomedicines President Christi Shaw
The Eli Lilly & Co. executive talked with Scrip about the competitive dynamics facing Taltz, the status of baricitinib and launching galcanezumab in the crowded CGRP class, as well as about industry issues like drug rebates, drug pricing and gender diversity.